CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICI) targeting either programmed cell death protein 1 (PD-1) or programmed cell death ligand 1 (PD-L1) have become routinely part of the clinical approach for the management of Non-Small Cell Lung Cancer (NSCLC)1.